BioCryst Pharmaceuticals, Inc. BCRX
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) is an immunology/inflammation drug developer. Its lead program, navenibart (STAR-0215), is in Phase 3 for Hereditary angioedema (HAE) prophylaxis.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ORLADEYO (berotralstat) | HAE prophylaxis | small molecule | Approved |
| navenibart (STAR-0215) | Hereditary angioedema (HAE) prophylaxis | antibody | Phase 3 |
| BCX17725 | Netherton syndrome | protein/peptide | Phase 1 |
Recent results and decisions
- approval FDA approved the supplemental New Drug Application for ORLADEYO 150 mg oral pellets for patients with hereditary angioedema aged 12 years and older.
In October, the FDA approved the company's supplemental New Drug Application for the use of the oral pellet formulation of once-daily ORLADEYO for patients with HAE aged 12 years and older.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 immunology/inflammation companies
- Sanofi SNY
- Argenx SE ARGX
- Roivant Sciences Ltd. ROIV
- Immunovant, Inc. IMVT
- Celldex Therapeutics, Inc. CLDX
- Biohaven Ltd. BHVN
- Zenas BioPharma ZBIO
- Nektar Therapeutics NKTR
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.